Luye Pharma provide customers with high-quality medications and professional services by leveraging Luye Pharma’s global R&D capabilities, global manufacturing facilities and global marketing networks.More
With over 30 healthcare facilities in Australia and Asia,Luye Medical is committed to provide patient-centred, value-based integrated healthcare services.More
Through real-time fluorescent qPCR and next-generation sequencing (NGS) technologies in combination with data platforms, Luye Diagnostics provides clinical, intelligent, complete solutions in different stages of the disease.More
Patronus Biotech, a subsidiary of Luye Life Sciences Group, focuses on the development, manufacturing and commercialization of new technology route vaccines and strives to be a pioneer in the industry.More
The drug is the world’s first innovative microsphere formulation for treating Parkinson’s Disease
It’s China’s First Long-acting Anti-IL-4Rα Monoclonal Antibody
To jointly build the Uzbekistan Innovative Vaccine Center
The NDA of this drug for the treatment of prostate cancer is also under review in China.
The world’s first drug that can produce long-term Continuous Dopaminergic Stimulation
Providing a new option for SCLC patients
The product has already received marketing authorization in multiple European countries.
For the Treatment of Metastatic Small Cell Lung Cancer
Showing a comprehensive antidepressant efficacy and a good safety profile
China’s first domestically created innovative injection of microspheres will benefit more patients
Five Themes for Common Prosperity∣
World-class Innovative Medical Service Model to Be Introduced to Achieve the "Healthy China 2030" Goal
Boan Biotech will be the first pharmaceutical company in China to implement Bio4C™ ProcessPad.
for treating Parkinson's disease (PD) and restless legs syndrome (RLS).
Clinical trials of the drug in Europe and the U.S. are making good progress
For treating Claudin18.2-positive advanced solid tumors.
LY03015 is used for the treatment of Tardive Dyskinesia and Huntington's Disease.
The results demonstrate LY03015’s high binding affinity for VMAT2 and excellent inhibition of DA uptake, indicating its potential clinical value.
For glycemic control in adult patients with type 2 diabetes.
For the treatment of mild to moderate dementia associated with Alzheimer’s disease
Treatment of Recurrent Glioblastoma
Over One Thousand Psychiatrists Gather to Discuss the Diagnosis and Treatment of Mental Disorders During COVID-19
Bringing new treatment option to patients.
The third biosimilar of Avastin® to enter the market in China
The results showed that the novel GalNAc moieties are more convenient and affordable.Compared with the traditional GalNAc.
The research demonstrates that LY-CovMab exhibits excellent neutralization potency against pseudovirus and authentic virus infection.
Brings Increased Clinical Benefits to Schizophrenia Patients through World-leading Microsphere Technology
Comprehensively Improving Symptoms of Depression with Triple Reuptake Inhibitor Profile
Demonstrating Strength of Luye Pharma’s World-Leading Microspheres Technology Platform
The study has provided guidance to clinical medication for the treatment of advanced squamous cell lung carcinoma.
LY03005 is an exclusive CNS product developed under Luye Pharma’s New Chemical and Therapeutic Entities (NCE/NTE) R&D platform.
This regional initiative aims to raise mental health awareness, supporting patients, physicians and health systems in overcoming the unmet needs, especially during the COVID-19 pan...